Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These two biotech stocks could be big winners in the years ahead.
Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation. First, the hard data supports bullishness in biotech stocks. According to Grand View Research, the underlying global industry reached a valuation of $1.55 trillion last year. Moving forward, experts project that the sector will expand at a compound annual growth rate (CAGR) of 13.96% from 2024 to 2030. At the culmination point, the space may be worth $3.88 trillion. Second, a sector r